New Avastin Breast Cancer Study Proposal Not Enough To Save Current Claim, ODAC Concludes

FDA's Oncologic Drugs Advisory Committee votes 6-0 for withdrawal of bevacizumab's accelerated approval for first-line metastatic breast cancer, despite Genentech's argument that the indication should be maintained while it conducts another confirmatory trial.